Our understanding of cancers has progressed rapidly as scientists have identified genetic anomalies, or DNA sequencing errors, that cause cancers to develop and grow. ArrayGenomics has focused on developing a test to reveal the genetic alterations that predict the recurrence of bladder cancer.
How genomic profiling throws new light on our understanding of cancers.
Many people with cancer are now living many years after their diagnosis. By providing an exact picture of the unique genetic make-up of your bladder cancer at any point in time, the BCA-1 Test gives you vital information about the current genomic profile of your cancer that can help you and your doctor to manage the disease. The BCA-1 Test can take away some of the uncertainty and give you the confidence to make decisions about your cancer journey.
Your doctor may also be able to use the BCA-1 Test result to help make earlier or more appropriate treatment decisions, reducing the impact of your bladder cancer on your everyday life.
Pioneers of genomic profiling and bladder cancer monitoring.
ArrayGenomics is a privately owned company founded on technology developed by a group of scientists and healthcare experts. Our mission is to help inform and develop personal care pathways for diseases such as bladder cancer where patients can have fast accurate, stress-free diagnosis and prognosis, followed by targeted effective treatments and monitoring.
Our vision is to change the way cancers are detected and monitored today, to bring better care for patients tomorrow.
Since 2009 we have worked with leading clinicians, hospitals and urological professionals in the United Kingdom, France and the United States to develop new non-invasive molecular tests for the early detection of cancer.
In 2017 we launched the BCA-1 Test, a non-invasive DNA test for the early prediction of staging and grading of bladder cancer from urine samples and covered by worldwide patents. This is now also available in the UK and we plan to introduce it to other countries in the near future.
New non-invasive molecular tests for kidney and prostate cancers are also in development.